Skip to main content
TRAX logo

TRAX · First Tracks Biotherapeutics, Inc. · Documents

Track TRAX — free
$44.79 +0.29 (+0.65%)
Market Cap
$1.87B
Shares
42.02M
Volume · Nov 19 98.53K Avg daily vol (3M) 827.63K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Quarterly report FY2026 Q3 Net loss $31.36M 10-Q filed Nov 3, 2026 Latest results ANB033 shows celiac protection; $200 million placement completed 8-K filed Nov 3, 2026
2026
Nov 17
Investor event
Celiac candidate nearly prevented gluten damage in trial

First Tracks said its lead celiac drug nearly prevented gluten-driven villous damage in a challenge study. Its second celiac trial, in more severe patients, reads out in the first quarter of next year.

3 source passages
we saw, in the context of an intense gluten challenge, almost a full prevention of deterioration That reads out in the first quarter of next year. the patients we're enrolling in the second cohort are more severe Open the document at this passage
Nov 16
Investor event
AMB033 celiac results support late-stage trials in 2027

First Tracks Bio reported AMB033 produced statistically significant celiac gluten-challenge results across histology and patient-reported symptoms, and committed to late-stage celiac trials in 2027. The healing-cohort readout is expected in the first quarter of 2027.

5 source passages
So First Tracks Bio, we are still technically a young company. One is AMB033. But what I'll start with is we recently announced statistically significant and compelling results, highly compelling results in a celiac trial in a gluten challenge frame. And we have committed publicly that we'll start late-stage trials in 2027. Cohort 2 has completed enrollment, and we will have those study results in the first quarter of 2027. Open the document at this passage
Nov 10
Investor event
CD122 celiac challenge shows best-in-class delta

First Tracks said its CD122 antagonist produced best-in-class celiac challenge results, plans four indications and late-stage celiac trials in 2027, and reported over $350 million in cash.

6 source passages
Our next presenting company, First Tracks from the company. So it is an antagonist of CD122, which presents in a receptor complex, either dimeric or trimeric receptor complex, on various types of immune cells. That's best in class in terms of the delta. A year from now, we will be in four indications being developed in at least two therapeutic areas for this drug. We'll be moving to late-stage trials for celiac disease and hopefully have released equally positive data in EOE. we are well-funded with over $350 million of cash sitting here today. I think we have enough assurance at this point that we will be able to start late-stage studies in 2027. Open the document at this passage
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
ANB033 shows positive celiac histology and symptom results

First Tracks Biotherapeutics said ANB033’s Phase 1b celiac Cohort 1 met histologic and symptom endpoints, with placebo-adjusted Vh:Cd improvement of +0.49 (p=0.009) and IEL reduction of -20.03 (p<0.001). Cash and cash equivalents totaled $155.6 million as of September 30, 2026.

Net loss $31.36M Diluted EPS -$0.88
Read from the MD&A section
5 source passages
First Tracks Biotherapeutics and EcoR1 Capital Fund Qualified, L.P. (“EcoR1”) entered into a securities purchase agreement On October 12, 2026, we announced top-line results from Cohort 1 (gluten challenge) of ANB033’s Phase 1b trial in celiac disease. ANB033 demonstrated a statistically significant difference compared to placebo across key histologic endpoints, including least squares (“LS”) mean change in villus height-to-crypt depth (“Vh:Cd”) ratio and intraepithelial lymphocyte (“IEL”) density, as well as symptom endpoints using the Celiac Disease Symptom Diary (“CDSD”). Specifically, ANB033 achieved an LS mean change from baseline in Vh:Cd ratio of -0.17 on ANB033 vs. -0.66 on placebo, a +0.49 placebo-adjusted delta (p=0.009), and an LS mean change from baseline in IEL density of -1.20 on ANB033 vs. +18.83 on placebo, a -20.03 placebo-adjusted delta (p<0.001). Cash and cash equivalents totaled $155.6 million as of September 30, 2026, compared to $311.6 million as of December 31, 2025. Open the document at this passage
Nov 3
Current report 8-K
ANB033 shows celiac protection; $200 million placement completed

First Tracks Biotherapeutics said ANB033 achieved statistically significant protection against gluten-induced intestinal damage and symptoms in a celiac disease Phase 1b cohort. It also completed a $200 million private placement, resulting in $343 million pro forma cash.

Financial results
2 source passages
ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms in Cohort 1 (gluten challenge) of Phase 1b trial in celiac disease (CeD) Completed private placement with $200 million in gross proceeds; pro forma cash of $343 million Open the document at this passage
Oct 26
Registration statement S-1
Registration statement

First Tracks Biotherapeutics registered 6,106,870 common shares for resale after a private placement at $32.75 per share, closed October 19, 2026, generated approximately $200 million in proceeds. The company will receive no proceeds from the sale.

Read from the first part of this long document
Oct 20
Current report 8-K Events of Oct 19
Entered into a material agreement

On October 19, 2026, First Tracks Biotherapeutics, Inc. closed a private placement of 6,106,870 common shares, par value $0.001 per share, and must file or confidentially submit a resale registration statement no later than 30 days after closing.

Read from the first part of this long document
Oct 15
Current report 8-K
Entered into a material agreement, Unregistered sale of equity, Regulation FD disclosure

First Tracks Biotherapeutics, Inc. entered a securities purchase agreement on October 15, 2026, to sell 6,106,870 shares of common stock at $32.75 per share in a private placement, for aggregate gross proceeds of approximately $200 million, expected to close October 19, 2026.

Read from the first part of this long document
Oct 13
Current report 8-K Events of Oct 12
Regulation FD disclosure, Other events

On October 12, 2026, First Tracks Biotherapeutics announced positive Phase 1b Cohort 1 results for ANB033 in celiac disease: a +0.49 placebo-adjusted Vh:Cd ratio delta (p=0.009), a -20.03 IEL density delta (p<0.001), and no safety signals observed to date.

Showing 1–19 of 19 documents
Key facts CIK 2091349 CUSIP 337185102 13F (30d) 178 filings 175 filers Visit website Investor relations